Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

First Tracks Biotherapeutics, Inc.

NASDAQ: TRAX · Life Sciences · 5 alerts · CIK 2091349

First Tracks Biotherapeutics, Inc. stories on ALFA USA NewsRead the news →
Share price
$46.56Close, Nov 16
Market cap
$1.96B
Shares outstanding
42.02MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All First Tracks Biotherapeutics, Inc. filings on SEC EDGAR ↗

4:24 PM ET 10-Q
Financial Results

First Tracks Biotherapeutics Q3 2026 Results: Net Loss of $31.4M, Loss Narrows

First Tracks Biotherapeutics completed its spin-off from AnaptysBio on April 20, 2026, and began trading under the symbol TRAX. For the nine months ended September 30, 2026, the company reported a net loss of $115.2 million, driven by $83.4 million in research and development expenses for its clinical-stage antibody therapies.

Key figure
Net loss $31.4M
4:19 PM ET 8-K
Financial Results

First Tracks Biotherapeutics Financial Results

First Tracks Biotherapeutics reported Q3 2026 financial results, highlighting a pro forma cash position of $343 million following a $200 million private placement. The company reported positive Phase 1b data for its lead candidate ANB033 in celiac disease and plans to initiate late-stage clinical development in 2027.

“ANB033, a subcutaneously administered CD122 antagonist designed to inhibit signaling of both IL-15 and IL-2 on immune cells, demonstrated statistically significant protection against gluten-induced intestinal damage and symptoms and was well tolerated in the Phase 1b gluten-challenge cohort. These data support our plans to progress ANB033 into late-stage development in 2027 in celiac disease as a potential treatment to prevent both acute symptoms and intestinal damage from gluten exposure despite general adherence to a gluten-free diet.”

Daniel Faga, president and chief executive officer
4:06 PM ET 8-K
Capital Raise

First Tracks Biotherapeutics Capital Raise

First Tracks Biotherapeutics, Inc. closed a private placement of 6,106,870 shares of common stock on October 19, 2026. In connection with the closing, the company entered into a registration rights agreement requiring it to file a resale registration statement for the investors within 30 days.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.